The long-term prognosis of hippocampal neurogenesis and behavioral changes of offspring from rats exposed to valproic acid during pregnancy.
attention deficit hyperactivity disorder
long-term
neurogenesis
offspring
prenatal toxicity
valproic acid
Journal
Neuropsychopharmacology reports
ISSN: 2574-173X
Titre abrégé: Neuropsychopharmacol Rep
Pays: United States
ID NLM: 101719700
Informations de publication
Date de publication:
06 2021
06 2021
Historique:
revised:
01
03
2021
received:
14
12
2020
accepted:
08
04
2021
pubmed:
6
5
2021
medline:
12
2
2022
entrez:
5
5
2021
Statut:
ppublish
Résumé
In pregnant women with epilepsy, it is essential to balance maternal safety and the potential teratogenicity of anticonvulsants. Recently, growing evidence has indicated that valproic acid (VPA) can produce postnatal congenital malformations and impair cognitive function. However, the mechanisms underlying cognitive dysfunction in long-term prognoses remain unclear. Pregnant Wistar rats received daily intraperitoneal injections of VPA (200 mg/kg/day) from embryonic day 12.5 until birth. On postnatal day (PD) 149, the rats received an injection of bromodeoxyuridine (BrdU). On PD 150, the rats were subjected to the open field (OF), elevated plus-maze (EPM), and Y-maze tests. After behavioral testing, perfusion fixation was performed and the brain was dissected for immunohistochemistry. A significant marked decrease was seen in the number of BrdU-positive cells in the dentate gyrus of offspring of VPA-treated dams compared to those of control. However, no significant differences in hyperactivity were found based on the results of the OF test among the offspring on PD 150 of 200 VPA-treated dams. In addition, no significant differences were seen in the EPM test. The behavioral abnormality observed in young offspring of VPA-treated dams was not significantly different from that of controls in adult offspring on PD 150. However, compared with controls, the number of BrdU-positive cells in VPA-treated rats was halved. The findings suggest that the behavioral abnormality seems to improve as they grow, even if some structural abnormalities may remain in the central nervous system.
Identifiants
pubmed: 33949804
doi: 10.1002/npr2.12181
pmc: PMC8340817
doi:
Substances chimiques
Valproic Acid
614OI1Z5WI
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
260-264Informations de copyright
© 2021 The Authors. Neuropsychopharmacology Reports published by John Wiley & Sons Australia, Ltd on behalf of the Japanese Society of Neuropsychopharmacology.
Références
Brain Res. 2019 Nov 15;1723:146403
pubmed: 31446017
Brain Res. 2013 Jan 23;1491:88-97
pubmed: 23123207
Arch Gen Psychiatry. 1993 Jul;50(7):565-76
pubmed: 8317950
Front Neurosci. 2016 Sep 21;10:424
pubmed: 27708559
Synapse. 2009 Sep;63(9):729-36
pubmed: 19425051
JAMA Netw Open. 2019 Jan 4;2(1):e186606
pubmed: 30646190
J Am Acad Child Adolesc Psychiatry. 2020 Sep;59(9):1069-1079
pubmed: 31449875
Autism Res. 2016 Sep;9(9):926-39
pubmed: 26714434
Neuropsychopharmacology. 2005 Jan;30(1):80-9
pubmed: 15238991
JAMA. 2013 Apr 24;309(16):1696-703
pubmed: 23613074
CNS Spectr. 2014 Aug;19(4):305-15
pubmed: 24571806
Am J Psychiatry. 2015 Oct;172(10):967-77
pubmed: 25998281
Am J Psychiatry. 2018 Feb 1;175(2):140-149
pubmed: 29050505
JAMA Psychiatry. 2016 Jul 1;73(7):705-12
pubmed: 27192050
Patholog Res Int. 2013;2013:712758
pubmed: 24381784
Stem Cell Reports. 2015 Dec 8;5(6):996-1009
pubmed: 26677766
Neuropsychopharmacol Rep. 2021 Jun;41(2):260-264
pubmed: 33949804
Neuroimage Clin. 2017 May 22;15:383-390
pubmed: 28580295
Epilepsy Behav. 2016 Nov;64(Pt A):62-68
pubmed: 27732918
Epilepsy Behav. 2017 May;70(Pt A):110-117
pubmed: 28412607